JPWO2019191279A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191279A5 JPWO2019191279A5 JP2020551912A JP2020551912A JPWO2019191279A5 JP WO2019191279 A5 JPWO2019191279 A5 JP WO2019191279A5 JP 2020551912 A JP2020551912 A JP 2020551912A JP 2020551912 A JP2020551912 A JP 2020551912A JP WO2019191279 A5 JPWO2019191279 A5 JP WO2019191279A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- mutations
- her2
- exon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims description 45
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 40
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 24
- 238000011319 anticancer therapy Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 230000002349 favourable effect Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010016629 fibroma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims description 2
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 208000010916 pituitary tumor Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044285 tracheal cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037964 urogenital cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 102000051957 human ERBB2 Human genes 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 208000029499 cancer-related condition Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648629P | 2018-03-27 | 2018-03-27 | |
| US62/648,629 | 2018-03-27 | ||
| US201862688049P | 2018-06-21 | 2018-06-21 | |
| US62/688,049 | 2018-06-21 | ||
| PCT/US2019/024353 WO2019191279A2 (fr) | 2018-03-27 | 2019-03-27 | Composés ayant une activité antitumorale contre des cellules cancéreuses portant des mutations her2 exon 19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519306A JP2021519306A (ja) | 2021-08-10 |
| JPWO2019191279A5 true JPWO2019191279A5 (fr) | 2022-04-01 |
| JP7386174B2 JP7386174B2 (ja) | 2023-11-24 |
Family
ID=68060750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551912A Active JP7386174B2 (ja) | 2018-03-27 | 2019-03-27 | Ｈｅｒ２エクソン１９変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210361655A1 (fr) |
| EP (1) | EP3773551B1 (fr) |
| JP (1) | JP7386174B2 (fr) |
| KR (1) | KR20200136417A (fr) |
| CN (1) | CN112088000A (fr) |
| AU (1) | AU2019243738B2 (fr) |
| BR (1) | BR112020019251A2 (fr) |
| CA (1) | CA3094108A1 (fr) |
| IL (1) | IL277373A (fr) |
| MX (1) | MX2020010121A (fr) |
| PH (1) | PH12020551495A1 (fr) |
| RU (1) | RU2020134932A (fr) |
| SG (1) | SG11202009498RA (fr) |
| WO (1) | WO2019191279A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210107023A (ko) * | 2018-12-21 | 2021-08-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 조합 요법 |
| WO2020205521A1 (fr) * | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Composés à activité antitumorale contre des cellules cancéreuses portant des insertions d'exon 20 d'egfr ou de her2 |
| WO2020214824A1 (fr) * | 2019-04-17 | 2020-10-22 | Board Of Regents, The University Of Texas System | Composés contre le cancer portant des mutations egfr résistantes aux inhibiteurs de la tyrosine kinase |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| WO1995001994A1 (fr) | 1993-07-09 | 1995-01-19 | Synergen, Inc. | Polypeptides ctla4 recombinants et procede de fabrication |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US5869245A (en) | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
| US5844905A (en) | 1996-07-09 | 1998-12-01 | International Business Machines Corporation | Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange |
| WO1998042752A1 (fr) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Peptides immunotherapeutiques se liant a ctla-4 |
| US6723564B2 (en) | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
| ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU784012B2 (en) | 1999-08-24 | 2006-01-12 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| AU2003233451A1 (en) | 2002-03-26 | 2003-10-13 | Massachusetts Institute Of Technology | Targets, methods, and reagents for diagnosis and treatment of schizophrenia |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| EP2439273B1 (fr) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (PD-1) et procédés de traitement du cancer à l'aide d'anticorps anti-PD-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| BRPI0812913B8 (pt) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos |
| MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
| EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| RS61136B1 (sr) | 2010-02-19 | 2020-12-31 | Xencor Inc | Novi ctla4-ig imunoadhezini |
| KR101217526B1 (ko) | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| BR112016001420A2 (pt) | 2013-08-02 | 2018-01-23 | Aduro Biotech Holdings Europe B V | combinação de agonistas de cd27 e inibição pontual imune para estimulação imune |
| US20180057603A1 (en) * | 2013-08-09 | 2018-03-01 | The Trustees Of The University Of Pennsylvania | Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers |
| CA3080200A1 (fr) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anticorps anti-pd1 et leur utilisation comme produits therapeutiques et produits de diagnostic |
| WO2016094904A1 (fr) * | 2014-12-12 | 2016-06-16 | Celcuity Llc | Procédés de mesure de l'activité de la voie de signalisation erbb pour diagnostiquer et traiter des patients atteints d'un cancer |
| EP3253733B1 (fr) * | 2015-02-05 | 2020-04-29 | TyrNovo Ltd. | Combinaisons de doubles modulateurs d'irs/stat3 et d'agents anticancéreux pour le traitement du cancer |
| CN110291104B (zh) * | 2016-11-17 | 2023-11-03 | 得克萨斯州大学系统董事会 | 具有针对携带egfr或her2外显子20突变之癌细胞的抗肿瘤活性的化合物 |
| KR20190054826A (ko) * | 2017-11-14 | 2019-05-22 | 한미약품 주식회사 | 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도 |
| KR20210107023A (ko) * | 2018-12-21 | 2021-08-31 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 암 치료를 위한 조합 요법 |
-
2019
- 2019-03-27 KR KR1020207029032A patent/KR20200136417A/ko unknown
- 2019-03-27 RU RU2020134932A patent/RU2020134932A/ru unknown
- 2019-03-27 US US17/042,012 patent/US20210361655A1/en active Pending
- 2019-03-27 CN CN201980022143.3A patent/CN112088000A/zh active Pending
- 2019-03-27 CA CA3094108A patent/CA3094108A1/fr active Pending
- 2019-03-27 SG SG11202009498RA patent/SG11202009498RA/en unknown
- 2019-03-27 MX MX2020010121A patent/MX2020010121A/es unknown
- 2019-03-27 EP EP19775368.4A patent/EP3773551B1/fr active Active
- 2019-03-27 BR BR112020019251-1A patent/BR112020019251A2/pt not_active IP Right Cessation
- 2019-03-27 AU AU2019243738A patent/AU2019243738B2/en not_active Expired - Fee Related
- 2019-03-27 JP JP2020551912A patent/JP7386174B2/ja active Active
- 2019-03-27 WO PCT/US2019/024353 patent/WO2019191279A2/fr unknown
-
2020
- 2020-09-15 IL IL277373A patent/IL277373A/en unknown
- 2020-09-17 PH PH12020551495A patent/PH12020551495A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502059A5 (fr) | ||
| US12054786B2 (en) | Methods for detecting CpG methylation and for diagnosing cancer | |
| ES2208766T3 (es) | Procedimiento de deteccion de mutaciones ki-ras y equipo para llevarlo a cabo. | |
| CN110799245B (zh) | 用于治疗具有非典型braf突变的癌症的组合物和方法 | |
| US20210008147A1 (en) | MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors | |
| CN106148498B (zh) | Kras基因突变检测试剂盒及其应用 | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| JP5651125B2 (ja) | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 | |
| US20180298447A1 (en) | Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation | |
| JPWO2020205521A5 (fr) | ||
| JPWO2019191279A5 (fr) | ||
| Tjebbes et al. | p53 tumor suppressor gene as a clonal marker in head and neck squamous cell carcinoma: p53 mutations in primary tumor and matched lymph node metastases | |
| CN112126681A (zh) | 一种检测人nras基因突变的pcr试剂盒 | |
| JP7334194B2 (ja) | Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法 | |
| JPWO2020205632A5 (fr) | ||
| Willson | AR blockers augment melanoma treatment | |
| JPWO2020214831A5 (fr) | ||
| Qi et al. | Identification of a novel crizotinib-sensitive NR-110219 & MIR4432-ALK gene fusion in a patient with lung adenocarcinoma by high-throughput sequencing of circulating tumor DNA and tumor-derived DNA from pleural effusion fluid | |
| Tingting et al. | Review and mechanism research of 30 cases of carcinoma showing thymus-like differentiation | |
| Ida et al. | PATH-24. RECURRENT UNUSUAL PATTERNS IN CLINICAL MOLECULAR PROFILING OF ADULT DIFFUSE GLIOMAS | |
| Xiaoyue et al. | Treatment and Research Progress of Advanced Non-Small Cell Lung Cancer with Rare Mutations | |
| 유승은 et al. | Clinical Response to ALK Inhibitors in a Metastatic Colon Cancer Patient with ALK-STRN Fusion Gene | |
| Wang et al. | P35. 10 Concomitant Driver Gene Mutations in Non-Small Cell Lung Cancer | |
| JPWO2020132633A5 (fr) | ||
| CN114807366A (zh) | 一种人肿瘤特异性braf突变检测方法 |